Cindy K. Miranti, PhD

Cancer Biology Program co-Leader
Cancer Biology Program, Research Member
Cindy K. Miranti, PhD

Biography

Cindy K. Miranti earned her B.Sc. in Microbiology from Southern Illinois University and her Master’s in Microbiology from Colorado State University. She then worked as a technician at National Jewish Hospital and the University of Colorado Health Sciences in the Eleanor Roosevelt Institute for Cancer Research. She then obtained her Ph.D in Biochemistry from Harvard Medical School working with Michael E. Greenberg on gene transcription. She then completed her postdoctoral training with Joan S. Brugge at ARIAD Pharmaceuticals and Harvard Medical School investigating cell adhesion in cancer development and metastasis. She then joined the Van Andel Research Institute in Grand Rapids, MI as an Assistant Professor and was promoted to Associate Professor. In 2016, she moved to University of Arizona in Tucson as full Professor in Cellular and Molecular Medicine and Leader of the Prostate Cancer Research Group in the Cancer Center. In 2017, she became Co-Leader of the Cancer Biology Program in the University of Arizona Cancer Center.

Cancer Focus

My laboratory investigates how cell adhesion through cell membrane proteins, called integrins, control the interactions of tumor cells with the surrounding tissues, and how they influence prostate cancer development, drug resistance, and bone metastasis. Our approach is to understand the normal biology of the prostate gland and the bone, to inform on the mechanisms by which tumor cells remodel and use those environments to develop, acquire hormonal resistance, and metastasize. Our research is focused in three primary areas: 1) developing in vitro and in vivo models that recapitulate human disease based on clinical pathology, 2) identifying pathways and molecules that could serve as clinical markers and/or therapeutic targets, and 3) defining the genetic events involved in normal prostate and bone development to determine how they are disrupted by cancer.